Posted by Michael Wonder on 28 Sep 2024
Dupixent (dupilumab) approved in China as the first ever biologic medicine for patients with chronic obstructive pulmonary disease
27 September 2024 - Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life.
Regeneron Pharmaceuticals and Sanofi today announced that the National Medical Products Administration in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease characterised by raised blood eosinophils.
